Abstract: Provided herein are, inter alia, humanized 1E9 antibodies capable of binding CD73. The humanized antibodies are useful for the treatment of cancer. Further provided are nucleic acids encoding humanized 1E9 antibodies and methods of inhibiting cell proliferation using the humanized antibodies provided herein.
Abstract: An isolated PD-L1 antibody whose binding to PD-L1 at acidic pH is substantially lower than its binding to PD-L1 at neutral pH at the same assay setting and an isolated PD-L1 antibody that is not pH dependent in binding to PD-L1 are provided. The pharmaceutical composition of the antibody, encoding polynucleotide and expression vector, isolated host cell thereof as well as a kit comprising the PD-L1 antibody are also provided. Also provided herein are methods of treating a PD-L1 associated condition using the PD-L1 antibody.
Abstract: Use of anti-Claudin 1 monoclonal antibodies and pharmaceutical compositions thereof, for the prevention and/or treatment of hepatocellular carcinoma in patients suffering from liver disease, in particular liver disease that is not associated with HCV infection or in patients who have been cured from HCV infection. Methods of preventing and/or treating hepatocellular carcinoma by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described. Experimental results with the hepatocarcinoma cell line HuH-7.5.1 are given.
Type:
Grant
Filed:
March 18, 2016
Date of Patent:
October 27, 2020
Assignees:
Institut Hospitalier Universitaire de Strasbourg, Institut National de la Sante et de la Recherche Medicale, Universite de Strasbourg
Inventors:
Thomas Baumert, Eric Robinet, Mirjam Zeisel
Abstract: Phosphatidylinositol 3-kinases (PI3Ks) are known to be important regulators of signaling pathways. To determine whether PI3Ks are genetically altered in cancers, we analyzed the sequences of the PI3K gene family and discovered that one family member, PIK3CA, is frequently mutated in cancers of the colon and other organs. The majority of mutations clustered near two positions within the PI3K helical or kinase domains. PIK3CA represents one of the most highly mutated oncogenes yet identified in human cancers and is useful as a diagnostic and therapeutic target.
Type:
Grant
Filed:
April 20, 2020
Date of Patent:
September 29, 2020
Assignee:
The Johns Hopkins University
Inventors:
Yardena Samuels, Victor E. Velculescu, Kenneth W. Kinzler, Bert Vogelstein
Abstract: This document provides methods and materials related to treating cancer (e.g., skin cancer). For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., Abraxane®/anti-VEGF polypeptide antibody complexes) to treat cancer (e.g., skin cancer) are provided.
Type:
Grant
Filed:
August 1, 2016
Date of Patent:
September 8, 2020
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: Hybridoma cell lines produce monoclonal antibodies that specifically bind to an APOBEC3 protein. The antibodies can be used in various methods. In some aspects, an anti-APOBEC3 antibody may be immobilized to a substrate. In another aspect, this disclosure provides a vector that includes a nucleic acid sequence encoding antibody produced by a hybridoma cell line that produces an antibody that specifically binds to an APOBEC3 protein.
Type:
Grant
Filed:
June 29, 2016
Date of Patent:
August 25, 2020
Assignee:
Regents of the University of Minnesota
Inventors:
Reuben S. Harris, William Brown, Michael Carpenter, Emily Law
Abstract: The invention relates to an isolated antigenic polypeptide comprising an epitope for binding an MCM2 monoclonal antibody, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of: (a) the amino acid as shown in FIG. 1; and (b) the amino acid sequence wherein said sequence is a variant polypeptide modified by addition, deletion or substitution of at least one amino acid residue as represented in FIG. 1.
Abstract: Methods are provided for treating a subject with prostate cancer and/or diagnosing a subject at risk for prostate cancer, which can include measuring increased expression of at least two prostate cancer-related molecules in a sample obtained from a subject, including the prostate cancer-related molecules AGR2, AGR3, CRISP3, CCL3, CEACAM5, CEACAM6, IL24, MMP9, CXCL14, CD90, POSTN, and SFRP4. The methods can include administering at therapy to a subject with prostate cancer. Methods are provided for treating a subject with intermediate- or high-risk prostate cancer, which can include measuring increased expression of MMP9 in a sample obtained from a subject compared to a control representing expression of MMP9 expected in a sample from a subject who has low-risk prostate cancer.
Type:
Grant
Filed:
December 12, 2017
Date of Patent:
July 28, 2020
Assignees:
Battelle Memorial Institute, University of Washington
Abstract: Phosphatidylinositol 3-kinases (PI3Ks) are known to be important regulators of signaling pathways. To determine whether PI3Ks are genetically altered in cancers, we analyzed the sequences of the PI3K gene family and discovered that one family member, PIK3CA, is frequently mutated in cancers of the colon and other organs. The majority of mutations clustered near two positions within the PI3K helical or kinase domains. PIK3CA represents one of the most highly mutated oncogenes yet identified in human cancers and is useful as a diagnostic and therapeutic target.
Type:
Grant
Filed:
December 8, 2017
Date of Patent:
July 7, 2020
Assignee:
The Johns Hopkins University
Inventors:
Yardena Samuels, Victor Velculescu, Kenneth Kinzler, Bert Vogelstein
Abstract: The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positiv metastatic breast cancer in patients who did not receive prior chemotherapy or biologic therapy with a HER2 antibody binding essentially to epitope 2C4, a HER2 antibody binding essentially to epitope 4D5, and a taxane. The invention further comprises extending survival of such patients by the combination therapy of the present invention. In a preferred embodiment, the treatment involves administration of trastuzumab, pertuzumab and docetaxel.
Type:
Grant
Filed:
October 13, 2016
Date of Patent:
June 23, 2020
Assignee:
GENENTECH, INC.
Inventors:
Virginia Paton, Anne Blackwood Chirchir, Pam Klein
Abstract: The invention provides a method for inhibiting an intracellular target in a cell with a bispecific antibody comprising contacting the cell with a bispecific antibody having a first Fv fragment with a cell-penetrating determinant and a second Fv fragment with an intracellular target-binding determinant under suitable conditions so that the first Fv fragment causes the bispecific antibody to enter the cell and the second Fv fragment binds the intracellular target in the cell and thereby inhibiting the intracellular target.
Type:
Grant
Filed:
February 11, 2016
Date of Patent:
June 16, 2020
Assignee:
The United States of America as represented by the Department of Veteran Affairs
Inventors:
Richard H. Weisbart, Robert N. Nishimura
Abstract: Compositions, e.g., compositions comprising cellular therapeutics and/or protein therapeutics, and methods of using such compositions for treating cancer are described.
Abstract: Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
Type:
Grant
Filed:
May 16, 2018
Date of Patent:
June 2, 2020
Assignees:
The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
Inventors:
Daphne Winifred Bell, Daniel A. Haber, Pasi Antero Janne, Bruce E. Johnson, Thomas J. Lynch, Matthew Meyerson, Juan Guillermo Paez, William R. Sellers, Jeffrey E. Settleman, Raffaella Sordella
Abstract: HER3 antigen-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the HER3 antigen-binding molecules.
Abstract: The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin ?4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.
Type:
Grant
Filed:
May 29, 2018
Date of Patent:
May 19, 2020
Assignee:
PROTHENA BIOSCIENCES LIMITED
Inventors:
Stephen Jed Tam, Yue Liu, Robin Barbour, Theodore Yednock, Kenneth Flanagan
Abstract: The present invention relates to agents capable of inhibiting the binding between Leptin and Neuropilin-1 (NRP1) and uses thereof in the therapeutic field.
Type:
Grant
Filed:
September 21, 2016
Date of Patent:
May 12, 2020
Assignees:
INSERM (Institut National de la Santé et de la Recherche Medicale), Fondation Imagine, Assistance Publique-Hopitaux de Paris (APHP), Université Paris Descartes, Centre National de la Recherche Scientifique (CNRS), Université de Bourgogne, CNAM—Conservatoire National des Arts at Metier
Abstract: The present invention provides an antibody having cross-linking ability against human Sema3A and mouse Sema3A. The antibody of the present invention can be used as therapeutic antibody drugs for inhibiting Sema3A in various cancers in which Sema3A expression is high, such as glioblastoma, pancreatic cancer and liver cancer. Since Sema3A is considered to be a therapeutic target of diabetic retinopathy, autoimmune arthritis, neuropathic pain and osteoporosis, the antibody of the present invention or an antigen binding fragment thereof can be used as a therapeutic agent for associated diseases in addition to an anti-cancer drug. The antibody of the present invention inhibits the growth of cancer cells derived from various carcinomas through inhibition of Sema3A function due to high anti-Sema3A binding, and inhibits the movement of cancer cells through inhibition of phosphorylation of ERK among Sema3A lower signaling substances.
Type:
Grant
Filed:
April 27, 2018
Date of Patent:
May 5, 2020
Assignees:
SAMSUNG LIFE PUBLIC WELFARE FOUNDATION, PANGEN BIOTECH INC.
Inventors:
Do Hyun Nam, Yong Jae Shin, Jae Hyun Lee